Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease, which presents with painful nodules, abscesses and sinus tracts. Patients suffer from pain, drainage and worsening of mental health and quality of life. Treatment is often difficult. HS is typically associated with obesity and metabolic syndrome; thus, antidiabetics, especially GLP-1 agonists, present a potential therapy option. The aim of this review was to analyze the effects of GLP-1 agonists on patients with HS, including on their cardiovascular risk and quality of life.A literature search was conducted on Embase and PubMed, yielding 300 papers, of which 10 were used for this review.HS patients using GLP-1 agonists showed improved clinical course with less pain and suppuration. Further, patients' quality of life and mental health improved and their cardiovascular risk was reduced. Inflammatory parameters showed no significant changes. Patients receiving a higher drug dose of GLP-1 agonists were more likely to show clinical improvement. A reduction in weight or BMI did not correlate with improvements in Hurley stage, pain or depression. Hence, HS patients could be treated with GLP-1 agonists.Therefore, whether patients' improvement is due to weight loss, or other mechanisms, i.e., GLP-1 agonists' anti-inflammatory properties, remains to be determined in further studies. Background: Methods: Results: Conclusions:
